O8

Sonoma Pharmaceuticals IncFRA Sonoma Stock Report

Last reporting period 30 Jun, 2024

Updated —

Last price

Market cap $B

0.003

Micro

Exchange

XFRA - Deutsche Boerse AG

O8Z3.F Stock Analysis

O8

Uncovered

Sonoma Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-26/100

Low score

Market cap $B

0.003

Dividend yield

Shares outstanding

4.649 B

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Acuicyn, Endocyn, OroGenix Oral Hygiene Rinse, Microdacyn60 Oral Care, Sinudox, MicrocynAH, Nanocyn Disinfectant & Sanitizer, Epicyn Antimicrobial Facial Cleanser, Levicyn Antimicrobial Dermal Spray, Levicyn Antipruritic Gel, Levicyn Antipruritic Spray Gel, Celacyn Scar Management Gel and Sebuderm Topical Gel. Acuicyn is an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes and helps manage red, itchy, crusty and inflamed eyes. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections. Celacyn offers scar management by protecting and moisturizing wound and scar sites.

View Section: Eyestock Rating